Mereo BioPharma’s CEO discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat

blonca9
Jul 3, 2024
1 min read

Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the clinical benefit to patients’ lives. Plus, the role that the company’s alvelestat program could play in lung conditions.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Mereo BioPharma’s CEO discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight